Details for Patent: 10,478,502
✉ Email this page to a colleague
Which drugs does patent 10,478,502 protect, and when does it expire?
Patent 10,478,502 protects BRYHALI and DUOBRII and is included in two NDAs.
This patent has twenty-six patent family members in nineteen countries.
Drugs Protected by US Patent 10,478,502
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | 10,478,502 | ⤷ Subscribe | Y | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS | ⤷ Subscribe | |||
Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | RX | Yes | Yes | 10,478,502 | ⤷ Subscribe | Y | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,478,502
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2011345240 | ⤷ Subscribe | |||
Brazil | 112013012476 | ⤷ Subscribe | |||
Canada | 2817524 | ⤷ Subscribe | |||
Canada | 3055328 | ⤷ Subscribe | |||
China | 103228281 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |